Iron Supplementation Guidelines for Patients with Sulfa Allergy and Ferrous Gluconate Intolerance

Oral Iron Alternatives

The American Gastroenterological Association recommends ferrous fumarate as a first-line alternative to ferrous gluconate, providing significantly higher elemental iron content (69-108 mg per tablet) compared to ferrous gluconate (27-38 mg per tablet), for patients who cannot tolerate ferrous gluconate 1, 2, 3
Ferrous bisglycinate demonstrates the most favorable GI side effect profile among oral iron formulations, with a lower frequency of black stools (8%) compared to ferrous fumarate (22%) or ferrous sulfate (31%), and is reasonably affordable at approximately $2.40 for 30 tablets 1

The American College of Gastroenterology suggests starting with once-daily dosing rather than divided doses to significantly reduce GI side effects while maintaining similar iron absorption, and limiting initial elemental iron to 50-100 mg per day 4
Avoid taking iron within one hour of tea or coffee consumption, as these are powerful inhibitors of iron absorption, to maximize iron absorption 1

The European Society for Medical Oncology recommends formulations allowing 1-2 infusions to replace iron deficits, such as low-molecular-weight iron dextran (1000 mg single dose, $405) or iron sucrose (200 mg bolus over 10 minutes), due to convenience and similar overall efficacy 1, 5, 6
Ferric carboxymaltose (750-1000 mg, 1-2 doses) is convenient but expensive ($3470) and carries risk of prolonged hypophosphatemia with repeated dosing, and should be used with caution in patients with poor nutrition or absorption 1

True allergy to IV iron is very rare—most reactions are complement activation-related pseudo-allergy, and for mild infusion reactions, stop the infusion and restart 15 minutes later at a slower rate, and avoid diphenhydramine as its side effects can mimic worsening reactions 1
Resuscitation facilities must be available for all IV iron administrations, and cross-reactivity between IV iron formulations is uncommon, allowing patients with hypersensitivity to one IV iron product to often safely receive another formulation 5, 6